Thierry André
YOU?
Author Swipe
View article: Organ‐sparing strategies in patients with <scp>MSI</scp> / <scp>dMMR</scp> tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making
Organ‐sparing strategies in patients with <span>MSI</span> / <span>dMMR</span> tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making Open
Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumor types and confers a characteristic microsatellite instability‐high (MSI‐H) molecular phenotype. The MSI‐H/dMMR phenotype may arise from a…
View article: Laser Sheet Dropsizing of Ethanol Jets in Supersonic Crossflows with Far Field Oblique Shocks
Laser Sheet Dropsizing of Ethanol Jets in Supersonic Crossflows with Far Field Oblique Shocks Open
Uniform mixing of a liquid injectant into a high momentum flux gaseous flow constitutes a significant engineering challenge with valuable applications. This study characterizes the Sauter mean diameter (SMD) of an ethanol jet in supersonic…
View article: Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer Open
Nivolumab alone and in combination with ipilimumab demonstrated durable clinical benefit in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer in the phase 2 CheckMate 14…
View article: Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study Open
We demonstrated progressive improvements in survival outcomes for patients with metastatic colorectal cancer receiving first-line oxaliplatin-based chemotherapy plus molecular targeted agents. The findings highlight the importance of bioma…
View article: The Definition of Cure in Colon Cancer
The Definition of Cure in Colon Cancer Open
Importance The definition of cure in stage II to III colon cancer (CC) remains unclear due to limitations in conventional end points, which include deaths and second primary tumors as events. These can complicate communication with patient…
View article: First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer Open
Background Patients with deficient mismatch repair (dMMR) and/or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) show marked sensitivity to immune checkpoint inhibitors (ICIs). Dual PD-1/CTLA-4 blockade with niv…
View article: Seismic Instrument for Asteroids (SIA): the RAMSES seismometer
Seismic Instrument for Asteroids (SIA): the RAMSES seismometer Open
The close encounter between asteroid Apophis and Earth in 2029 presents an unparalleled opportunity for the first in-situ seismic study of an asteroid. The Seismic Instrument for Asteroids (SIA) will be deployed to the surface of (99942) A…
View article: Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors Open
Importance Immune checkpoint inhibitors (ICIs) have dramatically transformed the therapeutic landscape of deficient mismatch repair/microsatellite unstable−high (dMMR/MSI-H) metastatic colorectal cancer (mCRC); however, ICI use is challeng…
View article: Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastases
Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastases Open
This work was supported by funding from institutional grants from Inserm, EFS, University of Bourgogne Franche-Comté, national found "Agence Nationale de la Recherche - ANR-JCJC: Projet HERIC and ANR-22-CE45-0007", and "La ligue contre le …
View article: Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 1
View article: Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Table S1
View article: Figure S3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 3
View article: Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 2
View article: Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 4
View article: Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database Open
PURPOSE Several lines of treatment can be used sequentially in patients with metastatic colorectal cancer. We investigated the evolution of patient/tumor characteristics and their prognostic impact across treatment lines to develop an over…
View article: Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study Open
Background Sarcopenia and growth differentiation factor 15 (GDF-15) are linked to poor cancer survival. In this exploratory analysis, we evaluated their interaction with nivolumab-ipilimumab efficacy in chemoresistant metastatic colorectal…
View article: Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database Open
Background Early tumor shrinkage and depth of response have emerged as potential prognostic indicators in metastatic colorectal cancer (CRC). However, their associations with overall survival, progression-free survival (PFS), and postprogr…
View article: A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers Open
Background Single-agent MEK1/2 inhibition has been disappointing in clinical trials targeting RAS mutant (MT) cancers, probably due to upstream receptor activation, resulting in resistance. We previously found that dual c-MET/MEK1/2 inhibi…
View article: Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer Open
Larotrectinib demonstrated long durability, extended survival and manageable safety in patients with TRK fusion GI cancer, including those with MSI-H CRC. This supports the wider adoption of next-generation sequencing testing for NTRK gene…
View article: Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis Open
Our analysis revealed that oxaliplatin-based chemotherapy offers a significant survival benefit in stage III CC patients with T3 tumors. In contrast, no survival benefit was observed for T1-2 or T4 patients. These results suggested that T …
View article: Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Table S1
View article: Figure 3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure 3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
OS according to treatment (regorafenib vs. placebo) in patients with chemorefractory mCRC in the CORRECT trial in patients with (A) STC1-low levels or (B) STC1-high levels (optimized cut-off*). *Optimized STC1 plasma levels: STC1 low: <1,4…
View article: Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Biomarkers for antiangiogenic drugs in chemorefractory metastatic colorectal cancer (mCRC) are lacking. We investigated the relationship between stanniocalcin 1 (STC1) and outcomes in patients treated with regorafenib in the TEXCAN and COR…
View article: Figure 1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure 1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
OS in patients with refractory mCRC from the TEXCAN study according to baseline plasma protein levels of (A) ANG2 and (B) STC1.
View article: Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials
Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials Open
Supplementary Figure 2